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Background: Thyrotoxic periodic paralysis (TPP) is a life-threatening channelopathy manifesting as recurrent
episodes of hypokalemia and muscle weakness in the presence of hyperthyroidism. Recent findings indicate defects
of inward rectifying K+ (Kir) channels are associated with some TPP patients. The associations are not only found in
Caucasian population (mainly Brazilian), but also in Singaporean population. However, potential genetic risk factors
for mainland Chinese patients, the largest group of TPP cases in the world, have been largely unexplored.
Methods: Samples of DNA from 127 individuals with TPP and 102 hyperthyroidism male controls self-reported as
mainland Chinese were collected from 5 clinical centers from Jan 2011 to Jan 2014. The KCNJ2 gene, KCNJ18 gene,
as well as loci polymorphisms (rs623011and rs312691) at 17q24.3 were directly sequenced in TPP patients and
controls. Clinical data were summarized from TPP participants for genotype/phenotype correlations.
Results: 3.1% of TPP cases harbored KCNJ18 gene mutations in mainland Chinese patients. Patients with KCNJ18
mutation had shorter attack duration, higher prevalence of muscle soreness and weakness recurrence than patients
without KCNJ18 mutation. The alleles at 17q24.3 (rs623011and rs312691) were more common in patients with TPP
than in controls, and therefore were significant risk factors for TPP (odds ratio, 11.94 and 10.57; 95% CI, 5.93-24.05
and 5.48-20.40; P = 1.81 × 10−14 and 1.07 × 10−14 respectively).
Conclusions: This study demonstrates that the KCNJ18 variants are only responsible for a small proportion of TPP
patients in mainland China. There are significant clinical differences between patients with KCNJ18 mutations and
patients without KCNJ18 mutations. In addition, the rs623011and rs312691 loci are significantly associated with TPP
patients in mainland China, and highlight the Kir2.1 channel as a causative target in TPP.
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Thyrotoxic periodic paralysis (TPP) is a disorder mani-
festing as recurrent episodes of hypokalemia and muscle
weakness in the presence of hyperthyroidism. The
condition may be life-threatening if breathing muscle
weakness leads to breathing failure, or if the low potas-
sium levels cause cardiac arrhythmias [1,2]. TPP is more
prevalent in Asian populations, especially in males
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unless otherwise stated.descent [3,4]. In Chinese populations, TPP occurs in up
to 13% of male thyrotoxic patients, while women are
predominantly affected by hyperthyroidism in the gen-
eral population [3,5]. The high incidence of TPP among
Asian people suggests that the basic defects may be
genetically determined [6].
Although the mechanism of TPP remains largely un-
certain, a few risk factors have been identified, such as
carbohydrate loads and rest following exercise [7]. When
the symptoms of thyrotoxicosis are separated from the
clinical picture, many features of this disease are similar
to those described in familial hypokalemic periodic par-
alysis [8]. The condition has been linked to mutations inis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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electrolytes across cell membranes [9]. So TPP is consi-
dered as an endocrine channelopathy with genetic back-
ground [10]. Recent findings indicate that defects of the
skeletal muscle-specific inward rectifying K+ (Kir) chan-
nel, Kir2.6, encoded by the KCNJ18 gene, is associate
with a proportion of TPP patients mainly from the
United States, Brazil, France and Singapore [11]. Other
important developments are that gene polymorphisms
(rs623011and rs312691) at 17q24.3 may affect the ex-
pression of KCNJ2 gene (encoding Kir2.1) in Hong Kong
and Thai populations [12,13]. In mainland China, the
largest group of patients with TPP in the world exists
[14]; however, the clinical and genetic features are sel-
dom explored in these patients. In our study, we aimed
to determine whether mutations in KCNJ2 and KCNJ18
exist in mainland Chinese patients, and assess whether
loci polymorphisms (rs623011and rs312691) at 17q24.3
are associated with mainland Chinese patients.
Methods
Subjects
One hundred and twenty-seven Chinese patients with TPP
were collected in five clinical centers (The First Affiliated
Hospital of Nanchang University, Navy General Hospital
of China, Affiliated Hospital Guiyang Medical College,
People Hospital of Shanxi Province, and Affiliated Hospital
of Jiujiang College) from January 2011 to January 2014.
Diagnostic criteria for TPP include: (1) acute limb paralysis
with lower motor neuron origin; (2) blood potassium con-
centration <3.5 mmol/L; (3) hyperthyroidism supported by
laboratory tests; (4) excluding familial hypokalemic peri-
odic paralysis and hypokalemic periodic paralysis caused
by other causes. All subjects were examined and inter-
viewed by at least two clinicians (Li X., Yao S., Xiang Y.,
Zhang X., Wu X., Wan H., and Hong D.), and then all of
medical data uniformly reanalyzed by Dr. Li and Dr. Hong.
In order to avoid the deviation of diagnosis, all patients
must first meet the diagnostic criteria 1 and 2, and then
accord with the diagnostic criteria 3 and 4. Controls of
102 hyperthyroid male patients without episodic weakness
during their hyperthyroid states were collected from the
First Affiliated Hospital of Nanchang University. All cases
and controls self-reported as mainland Chinese were male
and their etiology of hyperthyroidism was Graves’ disease.
This study was approved by the ethics committee of the
First Affiliated Hospital of Nanchang University. All parti-
cipants gave their written informed consent in compliance
with the Chinese bioethics laws as well as the Declaration
of Helsinki.
Genetic screening
Genomic DNA was extracted form peripheral blood of
TPP cases and controls. Coding exons of the KCNJ2 andKCNJ18 genes were amplified using polymerase chain
reaction (PCR) with intronic primers. The primers for
amplification of the KCNJ2 gene (NM000891.2) were F1: 5′
GCTCCCAGAGACACCCATC3′, R1: 5′CATGACTGC
GCCAATGATGA3′; and F2: 5′GACCCAGACAACCA
TAGGCT3′, R2: 5′CCCATCTTGACCAGTACCGT3′.
The primer for the KCNJ18 gene (NG033093) was F: 5′
ATGCTGTCCTCTCTGTTCC3′ and R: 5′GGGCCTCT
CCCCGGCCA3′. The primers for rs623011 and rs312691
were F: 5′TCAGTCAACCACAAACCACA3′, R: 5′CCA
GCCAAGGAGACAACAAT3′ and F: 5′TCATGCCTG
ACCTGTGTACA3′, R: 5′AGCACTGAGAAGAGGTTG
GG3′ respectively. After purification, PCR products were
directly sequenced with an ABI 3730 DNA analyzer
(Applied Biosystems, Inc., CA, USA). To exclude PCR
errors, all nucleotide variations were sequenced in reverse.
To exclude the possibility that KCNJ18 mutations repre-
sented polymorphisms, identical genomic fragments from
200 healthy Chinese controls were examined for the novel
mutations.
Statistical analysis
The association of the different clinical variables was an-
alyzed by univariate analysis. Continuous variables were
expressed as mean ± SD and were analyzed by t’-test.
Categorical variables were expressed as absolute number
and proportion of cases and were compared by two-tail
Fisher’s exact test. For genotype study, the allele and
genotype distributions of TPP patients and controls were
compared and evaluated in allelic, dominant and reces-
sive inheritance models by two-tail Fisher’s exact test.
Odds ratios (OR) and confidence intervals (CI) were calcu-
lated using the non-risk genotype (12 + 22) as reference. A
value of P < 0.05 was considered statistically significant. All
statistical studies were performed by SPSS 13.0 software.
Results
KCNJ18 gene mutation
In the KCNJ18 gene screening, genetic analysis revealed
4 patients with heterozygous point mutations in 127
TPP patients (4/127, 3.1%) (Additional file 1: Figure S1).
One nonsense variant was at c.376C > T, which in-
troduced a stop codon (p.Q126X). Two other novel mis-
sense mutations were c.1079A > C that caused threonine
substitution for lysine at residue 360 (p.K360T); and
c.1162G > A that resulted in a replacement of glutamate
with lysine at residue 388 (p.E388K). Substitution p.K360T
is predicted to affect protein function with a score of 0.00
in Sorting Intolerant From Tolerant (SIFT) software [15]
and a score of 0.988 in Polyphen2 software [16]. Sub-
stitution p.E388K is predicted to affect protein function
with a score of 0.03 in SIFT software and a score of 0.728
in Polyphen2 software. Blast software revealed that the
two mutant residues had high evolutional conservation in
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[17]. We also identified a variant (c.598G > C) leading to
the change of alanine to proline at residue 200 (p.A200P)
that was described in a Taiwanese with sporadic periodic
paralysis [18]. The novel mutations were not identified in
200 healthy controls of Chinese descent.
KCNJ2 gene related mutations
No genetic variants were identified in the KCNJ2 gene in
this cohort of TPP patients. However, the genetic poly-
morphisms of rs312691 and rs623011 nearby the KCNJ2
gene showed significant associations with TPP patients
from five clinical centers (Table 1) (Additional file 1:
Table S1 and S2). In rs623011, A is the minor allele (0.488
in Han Chinese in Beijing, China (CHB)) [19]. The allele
frequency increased to 0.772 (196/254) in TPP patients,
while A allele frequency was 0.461 (94/204) in hyper-
thyroid controls. In rs312691, C is minor allele (0.463 in
CHB) [19]. The allele frequency increased to 0.799 (203/
254) in TPP patients, while C allele frequency was 0.471
(96/204) in hyperthyroid controls. The polymorphisms
had great associations with TPP occurrence, but there are
no significant differences between clinical phenotype and
genotype. Interestingly, the four patients with KCNJ18
mutations carried A/G or G/G at rs623011, and C/T or
T/T at rs312691, while no homogenous minor genotypes
(A/A and C/C) were identified at the two alleles.
Clinical features of TPP
Four sporadic male patients harbored KCNJ18 gene mu-
tations (Table 2). The age at onset ranged from 19 to
25 years old (mean 21.75 ± 2.75). All subjects suffered
from severe limbs weakness when getting up in the
morning. In addition, three out of four patients com-
plained of muscle soreness or limb numbness. The course
of disease lasted for 2–8 (mean 4.8 ± 2.8) hours. Three
patients had strenuous exercise before the attacks. Se-
rum potassium was 1.6-2.4 mmol/L (normal reference
3.5-5.1 mmol/L) without abnormalities of serum mag-
nesium and phosphorus. Serum creatine kinase (CK) of all
patients was moderately elevated to 1205-1710U/L (nor-
mal reference 20-170U/L). Electrocardiogram showed a
typical u-wave without other abnormal electrophysiology.
The diagnosis of hyperthyroidism was not made before
the attacks of weakness; however, medical history sug-Table 1 Genotype associations of rs623011 and rs312691 wit
Case Control
Allele (1/2) 11 12 22 Frequency
of risk
allele (1)
11 12 22 Frequen
of risk
allele (1)
rs623011 A/G 78 40 9 0.772 12 70 20 0.461
rs312691 C/T 82 39 6 0.799 15 66 21 0.471
Odds ratios and confidence intervals were calculated using the non-risk genotype (gested that 3 patients had weight loss; 2 patients had mild
hand tremor; and 1 patient had mild goiter. Diagnosis of
hyperthyroidism was made in 4 patients based on thyroid
stimulating hormone (TSH) <0.03 mU/L (normal refe-
rence 0.35-4.95 mU/L), and increased level of free te-
traiodothyronine and free triiodothyronine. Weakness was
resolved after supplements of potassium. The symptom
recurred in 3 patients during the treatment, and one of
them had four episodes in the 13–28 months follow-up,
however, weakness did not occur again after remission of
hyperthyroidism.
Compared with patient with KCNJ18 variants (Table 3),
statistical analysis revealed TPP patients without KCNJ18
variants had a longer weakness duration ranging from
1 hour to 6 days (mean 27.6 ± 11.6 hours). In addition,
TPP patients without KCNJ18 variants had lower pre-
valence of muscle soreness or limb numbness, and lower
recurrence of muscle weakness. Except for the above
clinical variables, other clinical variables including age at
onset, quadriplegia, level of serum CK, and hyperthy-
roidism symptoms had no differences between patients
with KCNJ18 variants and without KCNJ18 variants.
The follow-up period (2–35 months) in patients without
KCNJ18 variants showed that episodic weakness did not
recur after remission of hyperthyroidism.
Discussion
Although the detailed mechanism of TPP remains un-
clear, TPP has been considered as a kind of channe-
lopathy disease, because its clinical pictures are very
similar to those of familial or sporadic hypokalemic pe-
riodic paralysis [1-3,6]. A milestone progression was
made by Ryan DP. and his colleagues in 2010 [11]. They
found that the defects of Kir2.6 were responsible for par-
tial TPP patients: 33.3% in Caucasian population (mainly
Brazilian), 25.9% in Singaporeans, and 1.2% in Hong Kong
people. In addition, 1.7% TPP patients from Taiwan were
identified with KCNJ18 variations, while mutations in
KCNJ18 were also identified in sporadic periodic paralysis
(SPP). It suggested that both SPP and TPP had the same
molecular basis [18]. Our systematic screening of 127 TPP
cases found 3 novel and 1 previously reported hetero-
zygous mutations in the KCNJ18 gene, indicating 3.1%
mainland Chinese TPP patients harbored these gene mu-
tations, which is a little higher than those in Hong Kongh TPP in mainland Chinese male patients
P-value




9.88 × 10−12 1.81 × 10−14 5.27 × 10−3 11.94 5.93-24.05
2.64 × 10−13 1.07 × 10−14 3.08 × 10−4 10.57 5.48-20.40
12 + 22) as reference.





Hyperthyroidism Potassium mmol/L CK IU/L TSH uIU/ml FT3 pg/ml FT4 ng/dl KCNJ18
mutation
1 Male/19 2 h Quadriplegia Weight loss, goiter 1.9 2093 <0.03 8.2 3.5 p.Q126X
2 Male/20 6 h Quadriplegia Weight loss 2.4 1476 <0.03 12.3 5.8 p.A200P
3 Male/23 3 h Quadriplegia Tremor 2.1 1205 <0.03 7.6 5.1 p.K360T
4 Male/25 8 h Quadriplegia Weight loss 1.6 2310 <0.03 16.8 9.3 p. E388K
Abbreviation: CK creatine kinase, TSH Thyroid Stimulating Hormone, FT3 free triiodothyronine, FT4 free thyroxine.
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and Singapore.
Since the first cases with KCNJ18 mutations were re-
ported in 2010, only 20 TPP cases with KCNJ18 muta-
tions had been described in the worldwide [11,18]. All of
the patients plus our four cases were male individuals,
while 2%-5% of TPP patients without KCNJ18 mutation
were female cases [5,6]. The episodic weakness in pa-
tients with KCNJ18 mutation was commonly resolved
within several hours, while the mean duration of our
non-KCNJ18 patients lasted for a longer period than
those of patients with KCNJ18 mutation. Meanwhile, we
observed patients with KCNJ18 mutation had a higher
prevalence of muscle soreness and weakness recurrence
than patients without KCNJ18 mutation. At present, the
total number of TPP patients with KCNJ18 mutations is
relatively small. In order to confirm the clinical pheno-
type of TPP patients with KCNJ18 mutations, more
cases should be analyzed and summarized in the future.
The KCNJ18 gene encodes Kir2.6 protein that is a spe-
cific muscle subtype of Kir2.x family [11]. Kir2.6 can
physically associate with Kir2.1 and Kir2.2 to form het-
erotetramers on sarcolemma. Through heterotetrameri-
zation of subunits, Kir2.6 may control Kir2.1 and Kir2.2Table 3 Analysis of clinical variables in TPP patients
between with KCNJ18 mutation and without KCNJ18
mutation
Variables With KCNJ18
mutations (n = 4)
Without KCNJ18
mutations (n = 123)
P value
Age 21.75 ± 2.75 25.23 ± 16.67 0.487
Sex (m/f) 4/0 (100%/0) 123/0 (100%/0) -
Weakness duration (h) 4.8 ± 2.8 27.6 ± 11.6 0.006
Soreness or
numbness
3 (75.0%) 21 (17.1%) 0.021
Quadriplegia 4 (100%) 66 (53.7%) 0.127
HyperCKmia 4 (100%) 75 (61.0%) 0.296
Hyperthyroidism symptoms
Tremor 2 (50.0%) 47 (38.2%) 0.639
Weight loss 3 (75.0%) 30 (24.4%) 0.054
Goiter 1 (25.0%) 12 (9.8%) 0.354
Weakness
recurrence
3 (75.0%) 26 (21.1%) 0.046abundance on the muscle plasma membrane, thus pro-
viding a mechanism to fine tune electrical responses
[20,21]. The KCNJ18 gene contains a thyroid-responsive
cis element within its promoter that may regulate gene
transcription [22]. Under the high thyroid hormone,
mutational KCNJ18 transcripts express lots of abnormal
Kir2.6, and thus a dominant negative trafficking pheno-
menon can lead to endoplasmic reticulum retention of
Kir2.x subunits [21]. Thus, mutational Kir2.6 may alter a
delicate protein abundance and balance of electrical ac-
tivity in muscle. In this study, the nonsense mutation
(p.Q126X) apparently will cause the loss of function in
Kir2.6 channel owing to the truncated protein. The
p.A200P mutation had been reported in a Taiwanese with
sporadic periodic paralysis, and no whole-cell current was
detected in the A200P mutant by in vitro electrophysio-
logical study [18]. As for the other two novel mutations
(p.K360T and p.E388K) with high evolutional conserva-
tion, the charge of amino acids will undergo great changes
(i.e. from strong positive charge of lysine to neutral charge
of threonine; from negative charge of glutamate to strong
positive charge of lysine). Although no functional data
were available on the two mutations from the literature,
the SIFT software and Polyphen2 software predicted the
mutations to be probably damaging. Meanwhile, in vitro
study had showed that p.T354M and p.K366R (nearby
p.K360T and p.E388K) produced small decrease in current
density and longer time required for half-maximal current
degradation respectively [11]. Although electrophysio-
logical studies of p.K360T and p.E388K have not been
done in our present study, the residues p.T354M and
p.K366R are located in intracellular C-terminal of Kir2.6,
which may affect downstream phyosphorylation of ion
channel signal conduction [11,21].
Kir2.1 (encoded by KCNJ2 gene) is highly expressed in
skeletal and cardiac muscles. It is one of important com-
ponents in the Kir2.x subfamily that are involved in the
determination of muscle electrical physiology, such as
resting membrane potential and cell excitability [20,23].
It is also known that Kir2.1 can physically integrate with
any one of the other Kir2.x proteins, such as Kir2.2,
Kir2.3, Kir2.4, and Kir2.6, to form heterotetramers on
cell membrane [20]. Although we could not find any
deleterious KCNJ2 mutations in our TPP cases through
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mutations lead to Andersen-Tawil syndrome (ATS) man-
ifesting as periodic paralysis, ventricular ectopy, and
dysmorphic features [24]. Both ATS and TPP are charac-
terized by periodic paralysis. Periodic paralysis occurs in
ATS independent of blood potassium concentration, but
periodic paralysis in TPP can occur only in the presence
of hypokalemia and thyrotoxic state. Both rs623011 and
rs312691 polymorphism are located at the 17q24.3
locus, ~75 kb and ~150 kb downstream of the KCNJ2
gene respectively. Transcriptional regulatory elements
of genes can be located at regions far away from the tar-
get transcriptional units [25]. In expression quantitative
trait locus (eQTL) analysis, the loci variants might affect
the expression of Kir2.1 and result in episodic weakness
similar to one of the clinical characteristics in ATS
patients [26].
Conclusions
The mutations in KCNJ18 are only responsible to a small
proportion of Chinese patients with TPP. Some clinical
symptoms (i.e. attack duration, muscle soreness, and
weakness recurrence) present with significant differences
between patients with KCNJ18 mutations and patients
without KCNJ18 mutations. We also demonstrate that
the genetic variants rs623011 and rs312691 at 17q24.3
locus are important risk factors for TPP patients in
mainland China.
Additional file
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mutant chromatograms of the KCNJ18 gene, and evolutional
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different clinical centers respectively.
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